Roger Stupp

Roger Stupp is the Chief of Neuro-oncology in the Department of Neurology and holds the Paul C. Bucy Professorship of Neurological Surgery at Northwestern University's Feinberg School of Medicine. He is also a Professor in Neurological Surgery, Medicine (Hematology and Oncology), and Neurology (Neuro-oncology). His research focuses on advancing treatments for brain tumors, particularly glioblastoma, through clinical trials and translational research. Dr. Stupp leads multiple active clinical trials evaluating novel therapies such as Debio 0123, L19TNF, and AZD9574 in combination with existing treatments like temozolomide and radiation therapy. His work integrates immunotherapy, targeted drug delivery across the blood-brain barrier, and innovative ultrasound technologies to improve outcomes for patients with malignant brain tumors.

He is a key contributor to the Robert H. Lurie Comprehensive Cancer Center’s Brain Tumor SPORE, a prestigious NCI-funded program advancing translational research in brain cancer. His research has led to breakthroughs in understanding the blood-brain barrier’s role in neurological diseases and discovering therapeutic targets like the STING pathway and TIM3 protein. Dr. Stupp’s clinical and scientific contributions have been featured in high-impact journals such as Nature Medicine and the Journal of Clinical Investigation.

Key grants include a $10.8 million NCI SPORE award renewal to expand translational brain tumor research. His team collaborates on cutting-edge trials at Northwestern Medicine, with locations across Chicago. Dr. Stupp’s work bridges laboratory discoveries with clinical practice, aiming to transform glioblastoma treatment paradigms through multidisciplinary approaches.